Tumor regression and survival after perioperative MAGIC-style chemotherapy in XXXX and gastroesophageal junction.

@entity5 @entity1 @entity356 @entity189
BACKGROUND: We assessed the effectiveness of perioperative MAGIC-style chemotherapy in our series focused on the @entity5 regression grade and survival rate. METHODS: We conducted a retrospective study of 53 @entity1 following a perioperative regimen of epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/X). Forty-four (83  %) @entity5 were located in the stomach and 9 (17  %) were located at the esophagogastric junction. Perioperative chemotherapy completion, resection, TNM staging, the @entity5 regression grade (Becker's classification) and survival were analyzed. RESULTS: Forty-five @entity1 (85  %) completed the 3 preoperative cycles. R0 resection was achieved in 42 (79  %) @entity1 . Thirty-five (66  %) @entity1 completed the 3 postoperative cycles. Nine @entity189 (17  %) were considered major responders after preoperative chemotherapy. With multivariate analysis, only completion of perioperative chemotherapy (HR: 0.25; 95%CI: 0.08 - 0.79; p   =   0.019) was identified as an independent prognostic factor for disease-specific survival. However, the protective effect of perioperative therapy was lost in @entity1 with ypT3-4 and more than 4 positive lymph nodes (HR: 1.16; 95%CI: 1.02 - 1.32; p   =   0.029). The @entity5 regression grade (major vs minor responders) was at the limit of significance only with univariate analysis. The 5-year overall and disease-specific survival rates were 18  % and 22  % respectively. CONCLUSIONS: The percentage of major responder @entity5 after preoperative chemotherapy was low. Completion of perioperative ECF/X chemotherapy may benefit @entity1 with @entity356 that do not invade the subserosa with few positive lymph nodes.
